Paid Clinical Trials Birmingham
Discover 905 paid clinical trials in Birmingham, Alabama. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Investigational CMV Vaccine Study for Volunteers Ages 9–15Investigational CMV Vaccine Study for Volunteers Ages 9–15
Sponsor:
Moderna
Location:
Code:
NCT05575492
Conditions
Cytomegalovirus
Eligibility Criteria
Sex: All
Age: 9 - 15
Healthy Volunteers: Accepted
Interventions
mRNA-1647
Placebo
The Arteriovenous Vascular (AV) ACCESS TrialThe Arteriovenous Vascular (AV) ACCESS Trial
Sponsor:
Wake Forest University Health Sciences
Location:
Code:
NCT04646226
Conditions
End-Stage Kidney Disease
Hemodialysis Complication
Eligibility Criteria
Sex: All
Age: 60+
Healthy Volunteers: Not accepted
Interventions
AV graft
surgical intervention for creation of a fistula
Cognitive Training Intervention and Attitudes Towards GeneticsCognitive Training Intervention and Attitudes Towards Genetics
Sponsor:
University of Alabama at Birmingham
Location:
Code:
NCT03094026
Conditions
Cognitive Impairment
Hematologic Neoplasms
Hematopoietic Cell Transplant
Eligibility Criteria
Sex: All
Age: 21+
Healthy Volunteers: Not accepted
Interventions
Lumosity
Lumosity (waitlist control)
Kidney Transplantation From Donors With HIV: Impact on Rejection and Long-Term Outcomes (Expanding HOPE Kidney)Kidney Transplantation From Donors With HIV: Impact on Rejection and Long-Term Outcomes (Expanding HOPE Kidney)
Sponsor:
Johns Hopkins University
Location:
Code:
NCT06263426
Conditions
Hiv
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
HIV D+/R+
HIV D-/R+
Virtual Walking Intervention for Neuropathic Pain in Spinal Cord InjuryVirtual Walking Intervention for Neuropathic Pain in Spinal Cord Injury
Sponsor:
Texas A&M University
Location:
Code:
NCT05005026
Conditions
Spinal Cord Injuries
Neuropathic Pain
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
VR Game 1
VR Game 2
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Sponsor:
Eli Lilly and Company
Location:
Code:
NCT05026866
Conditions
Alzheimer Disease
Eligibility Criteria
Sex: All
Age: 65 - 70+
Healthy Volunteers: Not accepted
Interventions
Donanemab
Placebo
Primary Subtalar Arthrodesis for Calcaneal FracturesPrimary Subtalar Arthrodesis for Calcaneal Fractures
Sponsor:
Wake Forest University Health Sciences
Location:
Code:
NCT06249126
Conditions
Calcaneus Fracture
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Primary Fusion (Open Reduction Internal Fixation (ORIF) + Primary Subtalar Arthrodesis (PSTA)
Open Reduction Internal Fixation (ORIF) only
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor TreatmentKRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
Sponsor:
Kartos Therapeutics, Inc.
Location:
Code:
NCT03662126
Conditions
Primary Myelofibrosis (PMF)
Post-Polycythemia Vera MF (Post-PV-MF)
Post-Essential Thrombocythemia MF (Post-ET-MF)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
KRT-232
Best Available Therapy (BAT)
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Sponsor:
NRG Oncology
Location:
Code:
NCT05879926
Conditions
Breast Cancer
Eligibility Criteria
Sex: Female
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Ovarian Function Suppression + Aromatase Inhibitor
Adjuvant Chemotherapy + Ovarian Function Suppression
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade GliomaA Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT03871257
Conditions
Low Grade Glioma
Neurofibromatosis Type 1
Visual Pathway Glioma
Eligibility Criteria
Sex: All
Age: 2 - 21
Healthy Volunteers: Not accepted
Interventions
Carboplatin
Magnetic Resonance Imaging
Quality-of-Life Assessment
Questionnaire Administration
Selumetinib Sulfate
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple MyelomaStudy of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Sponsor:
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Location:
Code:
NCT06297226
Conditions
Multiple Myeloma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Arlocabtagene Autoleucel (BMS-986393)